Corporate Governance Report

SNBL is pleased to announce that the English version of our Corporate Governance Report is now ready for stakeholders.

Read More

Notice Regarding Establishment of SDGs Committee

SNBL has established a Sustainable Developmental Goals (SDGs) committee.

Please see the link below for more details.

Read More

New brochures section

We have added a brochures section featuring overviews of our capabilities in antisense oligonucleotide therapeutics and gene therapy.
Please contact us at if you would like further information on our work in these areas at SNBL.

SNBL to participate in development of a prophylactic DNA vaccine for COVID-19

SNBL has announced their intention to participate in the development of a prophylactic DNA vaccine for SARS-CoV-2, the disease which causes COVID-19. The role of SNBL is to plan and conduct the preclinical safety studies of the DNA vaccine, which has collaboratively been developed by AnGes, Inc. and Osaka University, in order to conduct the clinical trial as early as possible.   This vaccine uses plasmid DNA technology which means that it can be produced faster than attenuated vaccines. DNA vaccines are safe and work by inoculating a plasmid encoding the protein of the target pathogen.


SNBL's mission is to free patients from suffering, by supporting drug development and improving medical technology, and participation in this project gives SNBL the chance to do so for those suffering from the novel coronavirus.




Japan's State of Emergency and SNBL

On April 7, 2020, Japanese Prime Minister Shinzo Abe declared a state of emergency in 7 areas of Japan due to COVID-19, including large cities such as Tokyo and Osaka. This does not apply to the areas in which SNBL's two major laboratories are located.

SNBL has already taken measures to keep our employees safe, such as increasing teleworking and securing supplies. We are doing what we can to keep people safe through research into vaccine and drug therapy safety.

SNBL is dedicated to business continuity while striking a balance with the safety of our employees, clients, and stakeholders. For more information on our business continuity plan, please contact



SNBL Client CytoDyn Files IND for Respiratory Complications Therapy due to COVID-19

Tokyo, Japan March 12, 2020  A client of Shin Nippon Biomedical Laboratories, Ltd. (hereafter, SNBL), CytoDyn Inc. (Vancouver, Washington, USA, hereafter CytoDyn) has filed an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) in order to conduct a Phase 2 clinical trial using leronlimab (PRO 140) as a therapy for patients who have respiratory complications as a result of the novel coronavirus disease 2019 (COVID-19). COVID-19 is the respiratory disease that may result from contraction of SARS-CoV-2, which was recently declared a global pandemic by the World Health Organization (WHO). Researchers all over the world are working on therapeutic pharmaceuticals to treat COVID-19, and SNBL would like to introduce CytoDyn’s therapy.

Although COVID-19 has spread throughout the world and is a threat to both individuals and to society, research and development of therapeutics is progressing at a rapid pace around the world, including at CytoDyn. SNBL Group’s mission is to free patients from suffering, by supporting drug development and improving medical technology, and we sincerely hope that that therapeutic drugs will reach patients as soon as possible. SNBL contributes to that mission by working with clients such as CytoDyn.


About Leronlimab and COVID-19

According to CytoDyn’s press release on March 9, 2020, their trial using leronlimab will focus on patients that develop mild-to-moderate respiratory illness after transmission of COVID-19.

CytoDyn president and Chief Executive Officer Nader Pourhassan, Ph.D. states that “we believe leronlimab could reduce the inflammation which contributes to Acute Respiratory Distress Syndrome (ARDS).” The migration into areas of inflammation of tregs, which can inhibit the innate immune response against pathogens, can be mitigated by Leronlimab.  The serious damage in the lungs exhibited by some patients is caused by migration of macrophages and the release of inflammatory cytokines including TNF and IL-6 (called a cytokine storm). 


About Leronlimab

The US FDA have granted CytoDyn a “Fast Track” designation for two potential indications of leronlimab; for HIV as a combination therapy with HAART and for metastatic triple-negative breast cancer.  In late 2019, CytoDyn announced that they signed agreements to commercialize leronlimab after securing manufacturing contracts. Leronlimab masks a cellular receptor that is important in HIV infection

Leronlimab’s target is CCR5, a cellular receptor that is immunologically important. The CCR5 receptor is a protein located on the surface of various cells, including leukocytes and cancer cells. On leukocytes, they act as receptors for chemoattractants called chemokines. The CCR5 receptor is also required for HIV to infect healthy T cells. Recent studies identified the CCR5 receptor as an important target for many disease processes, including cancer metastasis and certain immunological conditions.

Leronlimab is a unique humanized monoclonal antibody that belongs to a new class of HIV / AIDS treatments that prevents HIV from using the CCR5 receptor as an entry gateway for healthy cells and protects healthy cells from viral infections, in comparison with HAART, the current standard of care for HIV, which allows the virus to enter the cell and start replicating before it can attack the virus. Other benefits of leronlimab include an improved safety profile, longer half-life, and reduced dosing frequency.


About CytoDyn

CytoDyn is a biotechnology company focused on developing innovative treatments for multiple therapeutic indications. Their lead candidate compound, leronlimab, belongs to a new class of therapeutics called viral entry inhibitors, and is one of the most advanced experimental monoclonal antibodies for the treatment of HIV.


About SNBL

Shin Nippon Biomedical Laboratories, Ltd. (hereafter, SNBL) is a preclinical contract research organization (CRO) that was founded in Kagoshima, Japan in 1957. SNBL’s mission is to free patients from suffering, by supporting drug development and improving medical technology, and has focused since its founding on the preclinical studies necessary for the development of pharmaceuticals, medical devices, and products such as regenerative medicine. Preclinical safety studies in drug development are conducted to clarify the characteristics of new drug candidate compounds and their in vivo effects with reliable data. SNBL’s strength is conducting preclinical safety and efficacy studies, and pharmaceutical companies, biotech ventures, universities and research institutions trust SNBL to provide the data they need for their invaluable research.



SNBL at ACT2019


 SNBL will be exhibiting at the American College of Toxicology from November 17 to 20, 2019. If you are at ACT please pop by Booth #103 and let's chat about how we can support your drug development program. 


SNBL to be represented by Medgaea Life Sciences, Ltd. in Taiwan

 SNBL and Medgaea Life Sciences, Ltd. (MDG) have signed an agreement for Medgaea Life Sciences to represent SNBL in Taiwan.


The pharmaceutical industry is growing in Taiwan with government support, concentrated around biopharmaceuticals. With its close location and commitment to quality, SNBL is a great choice for preclinical contract research for Taiwanese organizations.


MDG was established in Taiwan in 2005 and offers a variety of preclinical contract research services for medical devices, health foods, pharmaceuticals, and herbal remedies. SNBL and MDG have an excellent cooperative relationship.


The partnership between SNBL and MDG will offer an abundance of support for R&D of pharmaceuticals, medical devices, and regenerative medicine in Taiwan.



Presenting at the Safety Pharmacology Society in Barcelona

At the Safety Pharmacology Society 2019, held in Barcelona from September 23-26, Tsuyoshi Uchino, who is one of SNBL's safety pharmacology experts will present a poster entitled "Utility of Heart Rate Variability Analysis in Telemeterized Cynomolgus Monkeys" on September 24 and 25. 


If you are attending SPS, please visit Tsuyoshi at Poster #134.


Otherwise please email if you are interested in obtaining a copy of the poster.

Gemseki chosen as Top 10 by magazine

Gemseki, a member of SNBL group, was chosen as one of the top 10 drug discovery service companies in APAC by Pharma Tech Outlook, and is the cover story for the the Safety Pharmacology Society 2019.


See a PDF link to the media release here.



Meet SNBL at Eurotox 2019





SNBL will be exhibiting at the 55th Eurotox Congress from 8 - 11 September in Helsinki, Finland.


Drop by Booth #61 or email to see how SNBL can provide preclinical support for your drug development program.